A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2018
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Blepharoptosis
- Focus Therapeutic Use
- Sponsors Osmotica Pharmaceutical; RevitaLid
- 09 Jul 2018 Status changed from not yet recruiting to recruiting.
- 09 Jul 2018 Planned End Date changed from 1 Jan 2019 to 28 Dec 2018.
- 09 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 13 Dec 2018.